Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy.

Next Previous
Trial Profile

Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriparatide (Primary) ; Zoledronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms SHOTZ
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 05 Oct 2013 Twenty-four month results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
  • 15 Oct 2012 Results from this trial presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), according to an Eli Lilly media release.
  • 22 Jun 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top